Table 1. Total studies included.
Study ID | Country | Total Number of Participants | Bystander Survival (S) or Neurological Outcome (N) | EMS Survival (S) or Neurological Outcome (N) |
Myerburg et al. 2002 [5] | United States | 420 | 17% S | 9% S |
Nakahara et al. 2015 [6] | Japan | 167912 | 40.70% S | 15% S |
Mitani et al. 2014 [7] | Japan | NA | 69% N | 35% N |
Kiyohara et al. 2017 [8] | Japan | NA | 77% S | 35% S |
Sun et al. 2020 [9] | Denmark | 653 | 32.30% S | NA |
Myat et al. 2019 [10] | Australia | 1299784 | 37.7% N | 22.6% N |
Nakashima et al. 2019 [11] | Japan | 28019 | 44% S | 31.80% S |
Kishimori et al. 2020 [12] | Japan | 1743 | 29.8% N | 9.7% N |
Siddiq et al. 2013 [13] | Canada | 1310 | 12.20% S | NA |
Caffrey et al. 2002 [14] | United States | 354 | 13% S | 7% S |
Culley et al. 2004 [15] | United States | NA | 50% S | NA |
Haskins et al. 2020 [16] | Australia | NA | 55.50% S | 28.80% S |
Kiguchi et al. 2019 [17] | Japan | NA | 51.80% S | 25.50% S |
Kitamura et al. 2010 [18] | Japan | 312,319 | 86% S | 78% S |
Kiyohara et al. 2019 [19] | Japan | 409 | 52.20% S | NA |
Swor et al. 2013 [20] | United States | 47 | 15.10% S | NA |
Ringh et al. 2015 [21] | Sweden | 6532 | 70% S | 31% S |
Murakami et al. 2014 [22] | Japan | 6190 | 10% S | NA |
Agerskov et al. 2015 [23] | Denmark | 2080 | 71.40% S | NA |
Kiyohara et al. 2016 [24] | Japan | 9978 | 19.4%N | 3% N |
Nielsen et al. 2013 [25] | Denmark | NA | 69% S | NA |
Capucci et al. 2016 [26] | Italy | 3271 | 41.40% S | 5.90% S |
Torney et al. 2020 [27] | UK | NA | 30.10% S | 16% S |
Iwami 2012 [28] | Japan | NA | 38.50% S | 18.20% S |
Sun et al. 2019 [29] | Denmark | 673 | 31.30% S | NA |
Kitamura et al. 2016 [30] | Japan | NA | 38.5% N | 18.2% N |
Haskins et al. 2022 [31] | Australia | NA | 39.60% S | 24.20% S |
Marenco et al. 2001 [32] | Canada | 2172 | 40.10% S | NA |
Shibahashi et al. 2021 [33] | Japan | 562 | 61.20% S | NA |
Odom et al. 2022 [34] | United States | NA | 19.70% S | 13.80% S |